The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2021
year mood +0.33 · +0.14 to +0.40 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan +0.40 Feb Mar Apr May Jun +0.14 Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.40+0.40+0.40+0.40+0.40+0.14+0.40+0.17+0.40+0.30+0.30+0.20

Vaccine revenue was a tens-of-billions windfall and reopening restored elective procedures, driving big-pharma and vaccine makers to peaks by late summer; but rising rates began mauling unprofitable small-cap biotech into year end.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2021
Jun
FDA approves Biogen's Aduhelm, first new Alzheimer's drug in 18 years npr.org →

The FDA approved Biogen and Eisai's Aduhelm under accelerated pathways despite advisory panel objections over inconclusive evidence of clinical benefit. The drug targets amyloid plaques in Alzheimer's patients but requires further trials to confirm efficacy, raising concerns over cost, patient access, and Medicare impact. Biogen's stock surged 39% following the announcement, reflecting market optimism amid controversy.

Aug
FDA grants full approval to Pfizer-BioNTech COVID vaccine cnbc.com →

The FDA granted full approval to Pfizer and BioNTech's COVID-19 vaccine, enhancing confidence in vaccine mandates by businesses, schools, and the military. The move allows Pfizer and BioNTech to market the vaccine directly and potentially increase pricing, with broader implications for vaccination rates and public health policy. The vaccine, now branded as Comirnaty, demonstrated 91% efficacy and met rigorous safety and manufacturing standards.